**REVIEW**

**WHAT ARE THE UNCOMMON ANAPLASTIC LYMPHOMA KINASE (ALK) FUSIONS IN NON-SMALL CELL LUNG CANCER?**

Dr Hind El Yacoubi¹, MD; Dr Mohamed SOW ², MD; Pr Hassan ERRIHANI ¹ ², MD PhD.

¹ Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
² Medical oncology department, National institute of oncology, Rabat, Morocco.

**ABSTRACT**

The lung cancer carcinogenesis is increasingly related to genetic disorders that lead to use specific targeted therapies which improve clinical outcome and survival. Gene fusion is one of the mechanisms of lung cancer pathogenesis besides gene mutation. The oncogenic echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene was the first described in non small cell lung cancer (NSCLC) and it’s the most frequent ALK rearrangement, which occurs in approximately 5% of NSCLC. The development of sequencing technology has allowed the discovery of other ALK partners that cause an ALK fusion in NSCLC. They are still less known, however. The aim of this review is to report the novel ALK fusions in NSCLC described in the literature and their particular characteristics. We will present the kinesin family member 5B (KIF5B) - ALK fusion, the huntingtin interacting protein 1 (HIP 1)- ALK fusion, and other uncommon ALK fusions.

**KEY WORDS:** ALK fusion, ALK partners, non-small cell lung cancer.

**Received** 18 April 2019; **Accepted** 26 April 2019; **Published** 27 April 2019

**Correspondence:** Dr Hind El Yacoubi, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.

Email: drhind@hotmail.fr

**Copyright © 2019 El Yacoubi Hind et al.**

This is an open access article distributed under the Creative Commons Attribution 4.0 International, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**INTRODUCTION**

Nowadays, advanced researches in genetic abnormalities and targeted therapies have modified the strategy of cancer care worldwide. These findings are applied in lung cancer treatment that has changed from non-specific cytotoxic agents to specific targeted agents. Anaplastic lymphoma kinase (ALK) gene fusion positive in lung cancer is an example for personalized medicine in a subset of patients. It was first recognized in 2007 by the discovery of the oncogenic echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene in approximately 5% of non-small-cell lung cancer (NSCLC) cases [1]. EML4 is the most common ALK fusion partner described in NSCLC. Other ALK partners are less known, however. It could be a source of a false negative diagnosis of ALK fusion in NSCLC that has a therapeutic implication. The confirmation of an ALK positive fusion in NSCLC leads to use specific ALK inhibitors that improve clinical outcome [2]. Thus, the determination of uncommon ALK partners may enhance prognosis for this patient’s subset. The aim of this review is to collect uncommon ALK fusion in NSCLC to help for a better care of these particular cases.

**THE KINESIN FAMILY MEMBER 5B (KIF5B) - ALK fusion**

KIF5B-ALK fusion is the most frequent after EML4-ALK in NSCLC [3-7]. It accounts for 0.42%-0.50% of the reported cohorts [3-4]. It consists of a gene rearrangement including portions of the KIF5B gene, which is located on the short arm of human chromosome...
10, and the ALK gene located on the short arm of human chromosome 2, in NSCLC cells [3]. Many fusion variants were reported indicating distinct breakpoints and fusion points within KIF5B and ALK gene [3-7]. These fusions occur mainly between exon 20 of ALK gene and three exon of KIF5B gene: exon 24 [3], exon 15 [4], and exon 17 [6]. Each of these KIF5B-ALK fusion genes would be expected to produce a functional protein tyrosine kinase that has a transforming potential, confirmed in an in vivo tumorogenicity assay [3]. In addition, KIF5B-ALK fusion activates survival signaling, strengthens cell proliferation, and improves cell migration and invasion [4]. The histopathology is predominated by adenocarcinoma [3,4,7] with papillary pattern [3,5]. Although, other histological type are reported, like adenosquamous carcinoma [6]. The pattern of immunohistochemistry (IHC) staining of KIF5B-ALK fusion is diffuse and cytoplasmic in some cases [3-4], however, some cells showed an unequal staining profile with a perinuclear halo [3]. The fluorescence in situ hybridization (FISH) analysis confirmed the presence of a translocation t(2;10) (p23:p11) responsible for the generation of KIF5B-ALK fusion [3]. The identification of KIF5B-ALK fusion variants was confirmed using polymeerase chain reaction (PCR) -based direct sequencing and/or reverse transcription polymeerase chain reaction (RT-PCR) [3-7]. Clinically, the small number of cases reported doesn’t allow concluding on specific clinical features for KIF5B-ALK rearrangement in NSCLC. It could occur in both men and women, two cases of three had a smoking history, two were stage IA and one was stage IV [4,5,7]. Both stage IA cases had surgery [4-5], with a locoregional and distant recurrence in one case [4]. Although, ALK inhibitors were not used in the reported cases to evaluate their efficacy to treat NSCLC with positive KIF5B-ALK fusion, they could be functional in this uncommon fusion because both KIF5B-ALK and EML4-ALK contain the tyrosine kinase domain of ALK which is the target of ALK inhibitors [8].

THE HUNTINGTIN INTERACTING PROTEIN 1 (HIP 1)- ALK fusion
Three variants of HIP 1- ALK fusion in NSCLC were reported in the literature [9-11]. They occurred between exon 20 of chromosome 2 and distinct fusion point of HIP 1 gene in chromosome 7: exon 21 [9], exon 28 [10], and exon 30 [11]. HIP 1-ALK fusion allows the production of a fusion protein that comprises the coiled-coil domain of HIP 1 and the juxtamembrane intracellular region of ALK [9-10], thus the ALK tyrosine kinase activity may be activated aberrantly facilitating oncogenesis in the lung [9]. Two cases were adenocarcinoma [9,11] and one case was a squamous cell carcinoma [10]. Clinically, two patients were women never smoker [9,11], and the third case was a man with a smoking history [10]. Two patients had a surgical resection [9,10], followed by adjuvant crizotinib therapy in one case without any recurrence [9]. There was one stage IV that received crizotinib for 5 months and then progressed, a second line treatment with alectinib achieved a complete response before progressing after one year [11]. These findings suggest that ALK inhibitors require further investigation in this subset of patients.

AUTHORS’ CONTRIBUTIONS
All the authors have actively participated in the redaction, the revision of the manuscript and provided approval for this final revised version.

Other uncommon ALK fusion
Seven other ALK partners are reported in NSCLC suggesting the diversity of this gene fusion [12-18]. Topaghi et al. described a case of kinesin-light chain 1(ALC)- ALK fusion in a woman aged 47 years with an in situ lung adenocarcinoma, a FISH assay confirmed the presence of t(2;14)(p23;q32.3), and the nucleotide sequencing revealed a fusion between exon 9 of KLC1 and exon 20 of ALK [12]. In 2014, Choi et al reported a novel fusion of translocated promoter region (TPR) and ALK in a 60-year-old man ex-smoker with a poorly differentiated lung adenocarcinoma, RT-PCR revealed a fusion of TPR exon 15 to ALK exon 20, and the genomic PCR confirmed the chromosomal translocation: t(2;14)(q31.1;p23) [13]. Another ALK partner was described by Shan et al in a woman aged 45 years ex-smoker, with a metastatic lung adenocarcinoma, ALK FISH was negative while IHC had a strong ALK expression, next generation sequencing revealed then a new ALK partner gene: baculoviral inhibition of apoptosis protein repeat containing six (BIRC6); the patient received crizotinib that achieved an objective response without progression[14]. In 2016, Kim et al reported a novel SEC31A-ALK rearrangement between SEC31A exon 20 and ALK exon 20 [14]. Histopathologically, it was a poorly differenciated lung adenocarcinoma with ALK FISH and IHC positive [15]. Gu et al described a particular case in a 69-year-old never smoker man who had an advanced lung adenocarcinoma harboring concomitant c-met overexpression, HER-2 amplification and a novel ALK fusion, namely spectrin beta non-erythrocitic 1(SPTBN1)-ALK fusion, which was created by an insertion between exon 6 of SPTBN1 gene and exon 20 of ALK gene [16]. Interestingly, the patient had an inherent resistance to crizotinib, chemotherapy, and radiotherapy with an overall survival of 8 months only; these data suggest that the coexistence of SPTBN1-ALK fusion, Met, and HER-2 may have been responsible for the failed response to treatment [16]. Two others ALK partners were reported tropomyosin-related kinase-fused gene (TFG) [17] and protein tyrosine phosphatase nonreceptor type 3 (PTP3N) [18], although the presence of TFG-ALK in lung cancer has not been proven with histopathological evidence [17]. The genetic structure analysis of PTPN3-ALK demonstrated that exons 10 and 11 of ALK have been translocated between exons 2 and 3 of PTPN3, then the ALK kinase domain is absent in the produced fusion protein, thus, the PTPN3-ALK fusion may not respond to crizotinib [18,19]. The biological and clinical significance of these ALK partners in NSCLC requires further investigation because it seems that not all of the above mentioned ALK rearrangements respond to ALK inhibitors.

CONCLUSION
Targeting ALK fusion in NSCLC is a helpful way to promote the prognosis and survival. Thus, the ALK fusion diagnosis should be more specific and performing to identify even uncommon ALK partners by using new technologies. Their cost is higher to be prescribed routinely, though. Future studies are needed to define the patient profile that is more likely candidate to deep investigation to look for uncommon ALK fusion.

COMPETING INTERESTS
The authors declare no competing interests.
REFERENCES

[1] Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.

[2] Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-2177.

[3] Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-3149.

[4] Wong D, Leung E, Wong S, et al. A Novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 2011;15:2709-2718.

[5] Kimura H, Nakajima T, Takeuchi K, et al. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. Lung Cancer 2012;75:66-72.

[6] Wang R, Pan Y, Li C, et al. The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res 2012;18:4725-4732.

[7] Wang Q, Yang X, He Y, et al. droplet digital PCR for absolute quantification of EML4-ALK gene rearrangement in lung adenocarcinoma. The Journal of Molecular Diagnostics 2015;17:515-520.

[8] Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.

[9] Hong M, Kim RN, Song JY, et al. HIP 1-ALK, a novel fusion protein identified in lung adenocarcinoma. Journal of Thoracic Oncology 2014;9:419-422.

[10] Fang D, Zhang B, Gu Q, et al. HIP 1-ALK, a novel alkid variant that responds to crizotinib. Journal of Thoracic Oncology 2014;9:285-294.

[11] Ou SL, Klempnner SJ, Greenbowe JR, et al. Identification of a novel HIP 1-ALK fusion variant in non-small-cell lung cancer and discovery of ALK I1171 mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. Journal of Thoracic Oncology 2014;9:1821-1825.

[12] Togashi Y, Soda M, Sakata S, et al. KLC1-ALK :a novel fusion in lung cancer identified using a formalin fixed paraffin embedded tissue only. Plos ONE 2012;7:e31323.

[13] Choi YL, Lira ME, Hong M, et al. A novel fusion of TPR and ALK in lung adenocarcinoma. Journal of Thoracic Oncology 2014;9:563-566.

[14] Shan L, Jiang P, Xu F, et al.BIRC6-ALK, a novel fusion gene in ALK break-apart FISH-negative lung adenocarcinoma, responds to crizotinib. Journal of Thoracic Oncology 2015;10:37-39.

[15] Kim RN, Choi YL, Lee MS, et al. SEC31A-ALK fusion gene in lung adenocarcinoma. Cancer Res Treat 2016;48:398-402.

[16] Gu FF, Zhang Y, Liu YY, et al. Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression and HER-2 amplification with inherent resistance to crizotinib chemotherapy and radiotherapy. Journal of Hematology and Oncology 2016;9:66.

[17] Rivoka K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203.

[18] Jung Y, Kim P, Keum J, et al. Discovery of ALK-PTPN3 gene fusion from human non-small-cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer 2012;51:590-597.

[19] Ou SH, Bartlett CH, Mino-Kinudson M, et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012;17:351-1375.